{"id":10137,"date":"2026-04-23T02:13:21","date_gmt":"2026-04-23T07:13:21","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10137"},"modified":"2026-04-23T02:24:51","modified_gmt":"2026-04-23T07:24:51","slug":"nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2026\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u30af\u30e9\u30b9\u6700\u9ad8\u306e\u6709\u52b9\u6027\u3001\u8010\u4e45\u6027\u3001\u5b89\u5168\u6027\u3092\u5f37\u8abf\u3059\u308b\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3<\/em><\/h3>

\u00a0<\/p>

\u30c6\u30ad\u30b5\u30b9\u5dde\u30c0\u30e9\u30b9\u30014\u670820\u65e5\u756a\u76ee<\/sup>, 2026<\/strong> \u2013 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u306b\u3088\u308b\u5149\u53d7\u5bb9\u4f53\u55aa\u5931\u304a\u3088\u3073\u8996\u899a\u969c\u5bb3\u306e\u60a3\u8005\u5411\u3051\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u7c73\u56fd\u8996\u899a\u30fb\u773c\u79d1\u5b66\u7814\u7a76\u5354\u4f1a\u306e \u3078\u306e\u53c2\u52a0\u304a\u3088\u3073\u767a\u8868\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002 ARVO 2026\u5e74\u5e74\u6b21\u7dcf\u4f1a<\/a> \u305d\u3057\u3066 Eyecelerator @ ARVO 2026<\/a> \u30b3\u30ed\u30e9\u30c9\u5dde\u30c7\u30f3\u30d0\u30fc\u306b\u3066\u3002.<\/p>

\u201c\u300cARVO\u3068Eyecelerator\u306b\u529b\u5f37\u3044\u5b58\u5728\u611f\u3092\u793a\u3057\u3001\u5f53\u793e\u306e\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u7642\u6cd5\u3067\u6cbb\u7642\u3092\u53d7\u3051\u305f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u60a3\u8005\u306b\u304a\u3051\u308b\u6709\u610f\u7fa9\u306a\u81e8\u5e8a\u52b9\u679c\u3092\u793a\u3059\u8ffd\u52a0\u7684\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u3092\u767a\u8868\u3067\u304d\u308b\u3053\u3068\u3092\u8a87\u308a\u306b\u601d\u3044\u307e\u3059\u300d\u3068\u3001Nanoscope\u306e\u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005\u3067\u3042\u308b\u30b5\u30df\u30e5\u30a8\u30eb\u30fb\u30d0\u30ed\u30f3\u533b\u5e2b\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c1\u56de\u306e\u6cbb\u7642\u3067\u6570\u5e74\u306b\u308f\u305f\u308b\u6301\u7d9a\u7684\u306a\u8996\u529b\u6539\u5584\u304c\u671f\u5f85\u3067\u304d\u308b\u3053\u3068\u306f\u3001\u60a3\u8005\u306b\u3068\u3063\u3066\u771f\u306b\u9769\u65b0\u7684\u306a\u5909\u5316\u3092\u3082\u305f\u3089\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u3001MCO-010\u306e\u5c06\u6765\u6027\u3092\u3055\u3089\u306b\u88cf\u4ed8\u3051\u308b\u3082\u306e\u3067\u3059\u3002BLA\u7533\u8acb\u306e\u5b8c\u4e86\u3068\u5546\u696d\u5316\u306b\u5411\u3051\u305f\u6e96\u5099\u304c\u9032\u3080\u306b\u3064\u308c\u3001Nanoscope\u306e\u52e2\u3044\u306f\u307e\u3059\u307e\u3059\u9ad8\u307e\u3063\u3066\u3044\u308b\u3068\u78ba\u4fe1\u3057\u3066\u3044\u307e\u3059\u3002\u300d\u201d<\/p>

\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/strong><\/p>

Eyecelerator @ ARVO 2026
<\/strong>5\u67081\u65e5\uff08\u91d1\uff09\u30bb\u30f3\u30c8<\/sup>, 2026
\u30d6\u30eb\u30fc\u30d0\u30fc\u30c9\u30fb\u30dc\u30fc\u30eb\u30eb\u30fc\u30e0\u3001\u30b3\u30ed\u30e9\u30c9\u30fb\u30b3\u30f3\u30d9\u30f3\u30b7\u30e7\u30f3\u30bb\u30f3\u30bf\u30fc\u3001\u30c7\u30f3\u30d0\u30fc\u3001\u30b3\u30ed\u30e9\u30c9\u5dde<\/p>

\u30d1\u30cd\u30ea\u30b9\u30c8\uff1a<\/strong> \u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3\u535a\u58eb\u3001\u793e\u9577\u517c\u6700\u9ad8\u79d1\u5b66\u8cac\u4efb\u8005
\u30bf\u30a4\u30c8\u30eb\uff1a<\/strong> \u518d\u751f\u533b\u7642\u306b\u3088\u3063\u3066\u8996\u529b\u6539\u5584\u306f\u5b9f\u73fe\u3059\u308b\u306e\u304b\uff1f
\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a<\/strong> S5
\u65e5\u6642\uff1a<\/strong> 5\u67081\u65e5\uff08\u91d1\uff09\u5348\u524d11\u664245\u5206\uff5e\u5348\u5f8c12\u664245\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/p>

\u00a0<\/p>

ARVO\uff08\u8996\u899a\u30fb\u773c\u79d1\u5b66\u7814\u7a76\u5354\u4f1a\uff09
<\/strong>5\u67083\u65e5\uff08\u65e5\uff09rd<\/sup> 5\u67087\u65e5\uff08\u6728\uff09\u307e\u3067\u756a\u76ee<\/sup>, 2026
\u30b3\u30ed\u30e9\u30c9\u30fb\u30b3\u30f3\u30d9\u30f3\u30b7\u30e7\u30f3\u30bb\u30f3\u30bf\u30fc\u3001\u30c7\u30f3\u30d0\u30fc\u3001\u30b3\u30ed\u30e9\u30c9\u5dde<\/p>

\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a<\/strong> \u30b5\u30a6\u30e9\u30f4\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3\u535a\u58eb
\u30bf\u30a4\u30c8\u30eb\uff1a<\/strong> \u8fd1\u8d64\u5916\u7dda\u30ec\u30fc\u30b6\u30fc\u6d3b\u6027\u5316\u91d1\u30ca\u30ce\u30ed\u30c3\u30c9\u3092\u4ecb\u3057\u305f\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u785d\u5b50\u4f53\u5185\u6295\u4e0e\u5f8c\u306e\u970a\u9577\u985e\u306b\u304a\u3051\u308b\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3MCO-020\u306e\u751f\u4f53\u5185\u5206\u5e03\u304a\u3088\u3073\u7db2\u819c\u767a\u73fe
\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a <\/strong>106\u3001AMD\uff1a\u65b0\u85ac\u3001\u9001\u9054\u30b7\u30b9\u30c6\u30e0\u3001\u304a\u3088\u3073\u4f5c\u7528\u6a5f\u5e8fI
\u65e5\u6642\uff1a<\/strong> 5\u67083\u65e5\uff08\u65e5\uff09\u5348\u524d8\u6642\uff5e\u5348\u524d9\u664245\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/p>

\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a<\/strong> \u30f4\u30a3\u30cb\u30c3\u30c8\u30fb\u30de\u30cf\u30b8\u30e3\u30f3\u535a\u58eb\uff08\u30b9\u30bf\u30f3\u30d5\u30a9\u30fc\u30c9\u5927\u5b66\u773c\u79d1\u5b66\u6559\u6388\u3001\u7814\u7a76\u62c5\u5f53\u526f\u90e8\u9577\uff09
\u30bf\u30a4\u30c8\u30eb\uff1a<\/strong> \u5149\u907a\u4f1d\u5b66\u7684REMAIN 3\u5e74\u9593\u7814\u7a76\u30c7\u30fc\u30bf \u2015 \u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u5bfe\u3059\u308bRESTORE\u7b2c2b\/3\u76f8\u8a66\u9a13\u306b\u304a\u3051\u308bMCO-010\u306b\u3088\u308b\u6301\u7d9a\u7684\u306a\u8996\u529b\u6539\u5584
\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a <\/strong>306\uff0e\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3
\u65e5\u6642\uff1a<\/strong> 5\u67085\u65e5\uff08\u706b\uff09\u5348\u524d8\u664230\u5206\uff5e\u5348\u524d8\u664245\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/p>

\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a<\/strong> \u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3\u535a\u58eb
\u30bf\u30a4\u30c8\u30eb\uff1a<\/strong> \u7247\u5074\u785d\u5b50\u4f53\u5185\u6295\u4e0e\u5f8c\u306eAAV MCO-010\u306e\u5bfe\u5074\u79fb\u690d\u304a\u3088\u3073\u7db2\u819c\u5f62\u8cea\u5c0e\u5165
\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a <\/strong>453\u3001\u907a\u4f1d\u5b50\u6cbb\u7642\u3068\u907a\u4f1d\u5b50\u7de8\u96c6
\u65e5\u6642\uff1a<\/strong> 5\u67086\u65e5\uff08\u6c34\uff09\u5348\u5f8c2\u6642\uff5e\u5348\u5f8c3\u664245\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/p>

\u201c\u300cRESTORE\u8a66\u9a13\u306e3\u5e74\u9593\u306e\u7d50\u679c\u306f\u3001MCO-010\u304c\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306e\u60a3\u8005\u306b\u6301\u7d9a\u7684\u306a\u6a5f\u80fd\u7684\u5229\u76ca\u3092\u3082\u305f\u3089\u3059\u3053\u3068\u3092\u5b9f\u8a3c\u3057\u3066\u304a\u308a\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u30a2\u30d7\u30ed\u30fc\u30c1\u306e\u53ef\u80fd\u6027\u3092\u3055\u3089\u306b\u88cf\u4ed8\u3051\u3066\u3044\u307e\u3059\u300d\u3068\u30a2\u30ec\u30f3\u30fb\u30db\u30fc\u533b\u5e2b\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002, \u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u7db2\u819c\u7814\u7a76\u90e8\u9577\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u6700\u9ad8\u533b\u7642\u9867\u554f<\/a>. \u300c\u975e\u30d2\u30c8\u970a\u9577\u985e\u306b\u304a\u3051\u308bMCO-010\uff08AAV\uff09\u304a\u3088\u3073MCO-020\uff08\u975e\u30a6\u30a4\u30eb\u30b9\u6027\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u95a2\u3059\u308b\u8ffd\u52a0\u30c7\u30fc\u30bf\u306f\u3001\u9001\u9054\u30c0\u30a4\u30ca\u30df\u30af\u30b9\u306b\u95a2\u3059\u308b\u6211\u3005\u306e\u7406\u89e3\u3092\u6df1\u3081\u3001\u3053\u308c\u3089\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u7d99\u7d9a\u7684\u306a\u767a\u5c55\u3092\u5f8c\u62bc\u3057\u3059\u308b\u3082\u306e\u3067\u3042\u308b\u3002\u300d\u201c<\/p>

ARVO\u4f1a\u8b70\u306e\u671f\u9593\u4e2d\u3001Nanoscope\u30c1\u30fc\u30e0\u306e\u30e1\u30f3\u30d0\u30fc\u306f\u30d6\u30fc\u30b96065\u306b\u3066\u5bfe\u5fdc\u3044\u305f\u3057\u307e\u3059\u3002.<\/p>

MCO\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3064\u3044\u3066
<\/strong>MCO\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306a\u3069\u306e\u5149\u53d7\u5bb9\u4f53\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u3092\u76ee\u7684\u3068\u3057\u305f\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u5358\u56de\u6295\u4e0e\u306e\u785d\u5b50\u4f53\u5185\u6cbb\u7642\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002MCO\u306f\u3001\u9ad8\u5bc6\u5ea6\u306e\u53cc\u6975\u7db2\u819c\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3057\u3066\u5149\u611f\u53d7\u6027\u3092\u6301\u305f\u305b\u308b\u3053\u3068\u3067\u3001\u5149\u53d7\u5bb9\u4f53\u6b7b\u5f8c\u306b\u6b8b\u5b58\u3059\u308b\u8996\u899a\u56de\u8def\u3092\u6d3b\u7528\u3057\u307e\u3059\u3002MCO\u6cbb\u7642\u306f\u3001\u907a\u4f1d\u5b50\u691c\u67fb\u3001\u4fb5\u8972\u7684\u306a\u624b\u8853\u3001\u307e\u305f\u306f\u7e70\u308a\u8fd4\u3057\u6295\u4e0e\u3092\u5fc5\u8981\u3068\u3057\u306a\u3044\u305f\u3081\u3001\u65e2\u5b58\u306e\u7db2\u819c\u8a3a\u7642\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u5185\u3067\u5e45\u5e83\u3044\u60a3\u8005\u306b\u9069\u7528\u53ef\u80fd\u3067\u3059\u3002.<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066
<\/strong>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\uff08NCT04945772<\/a>\uff09\u3001FDA\u3078\u306eBLA\u7533\u8acb\u304c\u9806\u6b21\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\uff08NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001 \u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a> 2026\u5e74\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30d5\u30a3\u30f3\u30fb\u30c7\u30a3\u30d5\u30a3\u30b7\u30eb\u75c7\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001SD\u306b\u3064\u3044\u3066\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u907a\u4f1d\u6027\u7db2\u819c\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\uff08IRD\uff09\u306b\u3064\u3044\u3066\u306fPMDA\u306e\u5148\u99c6\u3051\u6307\u5b9a\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3001IRD\u306b\u3064\u3044\u3066\u306fEMA\u304a\u3088\u3073SFDA\u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\uff08GA\uff09\u306b\u5bfe\u3059\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u306f2026\u5e74\u306b\u958b\u59cb\u4e88\u5b9a\u3067\u3059\u3002IND\u7533\u8acb\u6e96\u5099\u4e2d\u306e\u305d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>

\u63a5\u89e6\uff1a
<\/strong>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e
+1 (817) 857-1186
PR@nanostherapeutics.com<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Presentations to highlight Nanoscope\u2019s best-in-class efficacy, durability, and safety of optogenetic therapy platforms \u00a0 DALLAS, TX, April 20th, 2026 \u2013 Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced participation and presentations at the Association for Research in Vision and Ophthalmology\u2019s ARVO 2026 Annual Meeting and Eyecelerator @ ARVO 2026 in Denver, Colorado. \u201cWe\u2019re proud to have a strong presence at ARVO and Eyecelerator and to present additional evidence of meaningful clinical benefit in RP patients treated with our multi\u2011characteristic opsin (MCO) therapy,\u201d said Samuel Barone, MD, Chief Medical Officer of […]<\/p>\n","protected":false},"author":1,"featured_media":10138,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10137","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T07:13:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T07:24:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings\",\"datePublished\":\"2026-04-23T07:13:21+00:00\",\"dateModified\":\"2026-04-23T07:24:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\"},\"wordCount\":697,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"datePublished\":\"2026-04-23T07:13:21+00:00\",\"dateModified\":\"2026-04-23T07:24:51+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ARVO26_feature.jpg\",\"width\":960,\"height\":960},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/04\\\/23\\\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2026\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-04-23T07:13:21+00:00","article_modified_time":"2026-04-23T07:24:51+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings","datePublished":"2026-04-23T07:13:21+00:00","dateModified":"2026-04-23T07:24:51+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/"},"wordCount":697,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","url":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2026\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","datePublished":"2026-04-23T07:13:21+00:00","dateModified":"2026-04-23T07:24:51+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ARVO26_feature.jpg","width":960,"height":960},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/04\/23\/nanoscope-therapeutics-announces-participation-at-eyecelerator-and-arvo-2026-annual-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2026 Annual Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10137"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10137\/revisions"}],"predecessor-version":[{"id":10142,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10137\/revisions\/10142"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10138"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}